Prometheus Biosciences Inc, a biopharmaceutical company involved in the discovery, development, and commercialisation of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced yesterday that it has named Thierry Dervieux, PharmD, PhD, DABCC as its new chief development officer, diagnostics, and medical laboratory director.
Dr Dervieux joins Prometheus Biosciences from Exagen Diagnostics where he served as chief scientific officer and medical director. Prior to joining Exagen, Dr Dervieux was vice president of research and development at Cypress Bioscience Inc and senior director of research and development with Proprius Pharmaceuticals Inc. Prior to that, he served as principal scientist and director of research and development at Prometheus Laboratories.
Mark McKenna, chief executive officer of Prometheus Biosciences, said, 'Thierry's deep expertise in the development of innovative diagnostic assays and drug monitoring tools will benefit us greatly as we continue to advance our novel precision medicine platform for GI and autoimmune conditions. We are thrilled to welcome Thierry and we look forward to his contributions as we take Prometheus to the next level.'
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial